Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
Eric Santoni‐Rugiu, Linea Cecilie Melchior, Edyta Maria Urbanska, et al.
Cancers (2019) Vol. 11, Iss. 7, pp. 923-923
Open Access | Times Cited: 147

Showing 1-25 of 147 citing articles:

Overcoming therapy resistance in EGFR-mutant lung cancer
Antonio Passaro, Pasi A. Jänne, Tony Mok, et al.
Nature Cancer (2021) Vol. 2, Iss. 4, pp. 377-391
Closed Access | Times Cited: 353
Targeting non-coding RNAs to overcome cancer therapy resistance
Baoqing Chen, Mihnea P. Dragomir, Yang Chen, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 249
Aberrant m5C hypermethylation mediates intrinsic resistance to gefitinib through NSUN2/YBX1/QSOX1 axis in EGFR-mutant non-small-cell lung cancer
Yueqin Wang, Jingyao Wei, Luyao Feng, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 80
The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies
Alessandra Ferro, G.M. Marinato, C. Mulargiu, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 196, pp. 104295-104295
Open Access | Times Cited: 21
PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities
Xiaohong Liu, Wuxuan Mei, Pengfei Zhang, et al.
Pharmacological Research (2024) Vol. 202, pp. 107123-107123
Open Access | Times Cited: 18
Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy
Olga B. Garbuzenko, Andriy Kuzmov, Oleh Taratula, et al.
Theranostics (2019) Vol. 9, Iss. 26, pp. 8362-8376
Open Access | Times Cited: 111
Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers
Michael Offin, Romel Somwar, Natasha Rekhtman, et al.
JCO Precision Oncology (2018), Iss. 2, pp. 1-12
Open Access | Times Cited: 86
Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring
Damien Reita, L. Pabst, Erwan Pencreach, et al.
Cancers (2021) Vol. 13, Iss. 19, pp. 4926-4926
Open Access | Times Cited: 73
Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches
Saikat Ghosh, Ankit Javia, Saritha Shetty, et al.
Journal of Controlled Release (2021) Vol. 337, pp. 27-58
Closed Access | Times Cited: 66
Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies
Andreas Koulouris, Christos Tsagkaris, Anna Chiara Corriero, et al.
Cancers (2022) Vol. 14, Iss. 14, pp. 3337-3337
Open Access | Times Cited: 45
Designing strategies, structural activity relationship and biological activity of recently developed nitrogen containing heterocyclic compounds as epidermal growth factor receptor tyrosinase inhibitors
Rohit Pal, Ghanshyam Teli, Gurubasavaraja Swamy Purawarga Matada, et al.
Journal of Molecular Structure (2023) Vol. 1291, pp. 136021-136021
Closed Access | Times Cited: 36
Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance
Taisuke Araki, Shintaro Kanda, Hidehito Horinouchi, et al.
Japanese Journal of Clinical Oncology (2023) Vol. 53, Iss. 7, pp. 547-561
Open Access | Times Cited: 35
Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor
Yuesheng Zhang
Pharmacological Reviews (2023) Vol. 75, Iss. 6, pp. 1218-1232
Open Access | Times Cited: 33
Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer
Lee Jy, Richie R. Bhandare, Sai H. S. Boddu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 173, pp. 116275-116275
Open Access | Times Cited: 9
An acquired CCDC6:: RET gene fusion as resistance mechanism for Osimertinib in exon 21 EGFR(L858R) -mutated non-small cell lung cancer and its successful management with Osimertinib and Selpercatinib: a case report and review of literature
Maud Lormans, Peter Van Haecke, Ingel Demedts
Journal of Chemotherapy (2025), pp. 1-6
Closed Access | Times Cited: 1
A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinoma
Dantong Sun, Helei Hou, Feiyue Feng, et al.
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Mechanisms and therapeutic implications of gene expression regulation by circRNA-protein interactions in cancer
Nan Zhang, Xinjia Wang, Yu Li, et al.
Communications Biology (2025) Vol. 8, Iss. 1
Open Access | Times Cited: 1
LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers
Chen Chen, Wei-Ran Liu, Bin Zhang, et al.
Cancer Letters (2020) Vol. 486, pp. 58-70
Closed Access | Times Cited: 69
Formononetin inhibits tumor growth by suppression of EGFR-Akt-Mcl-1 axis in non-small cell lung cancer
Xinyou Yu, Feng Gao, Wěi Li, et al.
Journal of Experimental & Clinical Cancer Research (2020) Vol. 39, Iss. 1
Open Access | Times Cited: 53
Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer
Matin Shaikh, Yashodeep Shinde, Rahul Pawara, et al.
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 2, pp. 1008-1046
Closed Access | Times Cited: 52
Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients
Aliki Ntzifa, Αreti Strati, Galatea Kallergi, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 47
Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR
Irina Palacín-Aliana, Noemí Garcia‐Romero, Adriá Asensi-Puig, et al.
Biomedicines (2021) Vol. 9, Iss. 8, pp. 906-906
Open Access | Times Cited: 44
The importance of Ras in drug resistance in cancer
Fiona Healy, Ian A. Prior, David J. MacEwan
British Journal of Pharmacology (2021) Vol. 179, Iss. 12, pp. 2844-2867
Open Access | Times Cited: 43
Novel Angiogenic Regulators and Anti-Angiogenesis Drugs Targeting Angiogenesis Signaling Pathways: Perspectives for Targeting Angiogenesis in Lung Cancer
Yingying Li, Mengmeng Lin, Shiyuan Wang, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 29
The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies
Carmelo Laface, Felicia Maria Maselli, Anna Santoro, et al.
Pharmaceutics (2023) Vol. 15, Iss. 6, pp. 1604-1604
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top